CA2007983A1 - Coenzyme q10 avec inhibiteurs de la hmg-coa - Google Patents

Coenzyme q10 avec inhibiteurs de la hmg-coa

Info

Publication number
CA2007983A1
CA2007983A1 CA2007983A CA2007983A CA2007983A1 CA 2007983 A1 CA2007983 A1 CA 2007983A1 CA 2007983 A CA2007983 A CA 2007983A CA 2007983 A CA2007983 A CA 2007983A CA 2007983 A1 CA2007983 A1 CA 2007983A1
Authority
CA
Canada
Prior art keywords
hmg
coa reductase
coenzyme
effective amount
reductase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2007983A
Other languages
English (en)
Other versions
CA2007983C (fr
Inventor
Michael S. Brown
Jonathan A. Tobert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/298,535 external-priority patent/US4933165A/en
Priority claimed from US07/305,140 external-priority patent/US4929437A/en
Application filed by Individual filed Critical Individual
Publication of CA2007983A1 publication Critical patent/CA2007983A1/fr
Application granted granted Critical
Publication of CA2007983C publication Critical patent/CA2007983C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002007983A 1989-01-18 1990-01-17 Coenzyme q10 avec inhibiteurs de la hmg-coa Expired - Fee Related CA2007983C (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US298,535 1989-01-18
US07/298,535 US4933165A (en) 1989-01-18 1989-01-18 Coenzyme Q10 with HMG-CoA reductase inhibitors
US305,140 1989-02-02
US07/305,140 US4929437A (en) 1989-02-02 1989-02-02 Coenzyme Q10 with HMG-CoA reductase inhibitors

Publications (2)

Publication Number Publication Date
CA2007983A1 true CA2007983A1 (fr) 1990-07-18
CA2007983C CA2007983C (fr) 1996-12-10

Family

ID=26970727

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002007983A Expired - Fee Related CA2007983C (fr) 1989-01-18 1990-01-17 Coenzyme q10 avec inhibiteurs de la hmg-coa

Country Status (4)

Country Link
EP (1) EP0383432B1 (fr)
JP (1) JPH02233611A (fr)
CA (1) CA2007983C (fr)
DE (1) DE69001146T2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20014218A3 (cs) * 1999-06-08 2002-04-17 Sigma-Tau Industrie Farmaceutiche Riunite S. P. A. Antilipemické kombinace obsahující inhibitory HMG-KoA reduktázy a karnitiny
ATE288751T1 (de) * 1999-06-30 2005-02-15 Sigma Tau Ind Farmaceuti Lipidsenkende kombination, die im wesentlichen frei ist von toxischen wirkungen und nebenwirkungen der lipidsenker
US8753675B1 (en) 2000-01-20 2014-06-17 Raj K. Chopra Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
KR100846641B1 (ko) 2000-05-09 2008-07-16 카네카 코포레이션 동맥경화 억제 방법 및 조성물
AUPR177300A0 (en) * 2000-11-29 2000-12-21 Centre For Molecular Biology And Medicine Therapeutic methods
AUPR951101A0 (en) * 2001-12-13 2002-01-24 Centre For Molecular Biology And Medicine Method of treatment
ITRM20040307A1 (it) 2004-06-23 2004-09-23 Sigma Tau Ind Farmaceuti Confezione per almeno due prodotti differenti da vendere e utilizzare insieme.
WO2006057209A1 (fr) * 2004-11-26 2006-06-01 Sankyo Company, Limited Preparation pharmaceutique pour la diminution du taux sanguin en acides gras libres
JP4896501B2 (ja) * 2004-11-26 2012-03-14 第一三共株式会社 血中遊離脂肪酸低下作用を有する医薬組成物
US20080160001A1 (en) * 2005-03-28 2008-07-03 Pficker Pharmaceuticals Ltd. Antihypercholesterolemic Formulation with Less Side-Effects
TW200722077A (en) * 2005-03-29 2007-06-16 Kaneka Corp Composition for enhancing expression and activity of protease in liver
CN101491550B (zh) * 2008-01-22 2011-12-28 沈阳皓天万嘉医药科技有限公司 一种红曲提取物与辅酶q10复方制剂的制备方法
MX2010009290A (es) 2008-02-29 2010-09-14 Biolab Sanus Farmaceutica Ltda Composicion farmaceutica.
US8557236B2 (en) 2010-02-09 2013-10-15 Vascure Natural LLC Cardiovascular support supplement and compositions and methods thereof
EP2815654A1 (fr) 2013-06-21 2014-12-24 Essential IP BV Composition ayant un effet bénéfique sur le système cardio-vasculaire, contenant moacoline K, du lycopene et de la vatamine D3

Also Published As

Publication number Publication date
JPH02233611A (ja) 1990-09-17
CA2007983C (fr) 1996-12-10
EP0383432A1 (fr) 1990-08-22
EP0383432B1 (fr) 1993-03-24
DE69001146T2 (de) 1993-10-07
DE69001146D1 (de) 1993-04-29

Similar Documents

Publication Publication Date Title
CA2150372A1 (fr) Composition orale stable de ci-981 et procede de preparation
CA2273298A1 (fr) Produit et methode de traitement de l'hyperlipidemie
EP0433842A3 (en) 1,2,3-triazole derivatives active as inhibitors of the enzyme hmg-coa reductase and pharmaceutical compositions containing them
ZA929642B (en) Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor compound.
AU6084686A (en) Novel hmg-coa reductase inhibitors
HUT50804A (en) Process for lactonization of mevinic acid and analogs thereof
CA2268437A1 (fr) Naringine et naringenine utilisees en tant qu'inhibiteur de 3-hydroxy-3-methyl-glutaryl coenzyme a (hmg coa) reductase
IL86464A0 (en) Phosphorus-containing hmg-coa reductase inhibitor compounds and pharmaceutical compositions containing the same
JPS6426535A (en) Novel hmg-coa reductase inhibitor
AU4041293A (en) Phenylderivate as inhibitors of atp citrate lyase
AU6527090A (en) Substituted cyclohexene derivatives as hmg-coa reductase inhibitors
MY125051A (en) Antithrombotic and antiatherogenic pharmaceutical composition including a thienopyridine derivative and an hmg-coa-reductase inhibitor
SG48750A1 (en) Tricyclic carbonate compounds useful for inhabition of g-protein function for treatment of proliferative diseases
AU2058992A (en) HMG-COA reductase inhibitors
CA2135751A1 (fr) Derives de 4-mercaptoacetylamino-[2] benzazepinone(3) et leur utilisation comme inhibiteurs de l'enkephalinase
CA2128142A1 (fr) Combinaison pharmaceutique contenant un inhibiteur ras et un antagoniste d'endotheline pour le traitement des maladies cardiovasculaires
EP0648492A3 (fr) Inhibition de phosphatidylinositol-3-kinase avec viridin, diméthoxyviridin, viridiol, diméthoxyviridiol, virone, wortmannolone, et leurs dérivés.
EP0403487A4 (en) Novel hmg-coa reductase inhibitors
AU7126691A (en) Phosphorus-containing hmg-coa reductase inhibitors, new intermediates and method
JPS5792006A (en) Solid containing magnesium
DE69001146D1 (de) Koenzym q10 mit hmg-coa-reduktase-inhibitoren.
AU2175088A (en) Novel hmg-coa reductase inhibitors
EP0323866A3 (en) Novel hmg-coa reductase inhibitors
IT1237792B (it) Composti attivi come inibitori dell'enzima hmg-coa reduttasi
EP0657451A3 (fr) Dérivés de pyrrolidine comme inhibiteurs de la biosynthèse leucotriénique.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed